Ropinirole free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525325

CAS#: 91374-21-9 (free base)

Description: Ropinirole, also know nas AS-041164, SKF 101468, is a potent and selective PI3Kgamma inhibitor. Ropinirole is prescribed for mainly Parkinson's disease, RLS and extrapyramidal symptoms. It can also reduce the side effects caused by selective serotonin reuptake inhibitors, including Parkinsonism syndrome as well as sexual dysfunction and erectile dysfunction caused by either SSRIs or antipsychotics.

Chemical Structure

img
Ropinirole free base
CAS# 91374-21-9 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 525325
Name: Ropinirole free base
CAS#: 91374-21-9 (free base)
Chemical Formula: C16H24N2O
Exact Mass: 260.19
Molecular Weight: 260.381
Elemental Analysis: C, 73.81; H, 9.29; N, 10.76; O, 6.14

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 91374-20-8 (HCl)   91374-21-9 (free base)    

Synonym: Ropinirole free base; Ropinirole; SKF 101468; SKF-101,468; SKF 101468; AS-041164; AS 041164; AS041164;

IUPAC/Chemical Name: 4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one

InChi Key: UHSKFQJFRQCDBE-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19)

SMILES Code: O=C1NC2=C(C(CCN(CCC)CCC)=CC=C2)C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 260.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Mochizuki H, Hattori N, Hasegawa K, Nomoto M, Uchida E, Terahara T, Okawa K, Fukuta H. Long-term study of ropinirole patch in Parkinson's disease patients with/without basal l-dopa. Parkinsonism Relat Disord. 2021 Feb;83:105-109. doi: 10.1016/j.parkreldis.2020.12.023. Epub 2021 Jan 11. PMID: 33497892.


2: Nehal N, Nabi B, Rehman S, Pathak A, Iqubal A, Khan SA, Yar MS, Parvez S, Baboota S, Ali J. Chitosan coated synergistically engineered nanoemulsion of Ropinirole and nigella oil in the management of Parkinson's disease: Formulation perspective and In vitro and In vivo assessment. Int J Biol Macromol. 2021 Jan 15;167:605-619. doi: 10.1016/j.ijbiomac.2020.11.207. Epub 2020 Dec 2. PMID: 33278450.


3: Di Prima G, Campisi G, De Caro V. Amorphous Ropinirole-Loaded Mucoadhesive Buccal Film: A Potential Patient-Friendly Tool to Improve Drug Pharmacokinetic Profile and Effectiveness. J Pers Med. 2020 Nov 25;10(4):242. doi: 10.3390/jpm10040242. PMID: 33255761; PMCID: PMC7711624.


4: Russell B, Barrus MM, Tremblay M, Ma L, Hrelja K, Wong C, Hynes TJ, Hobson S, Grottick AJ, Winstanley CA. GPR52 agonists attenuate ropinirole-induced preference for uncertain outcomes. Behav Neurosci. 2020 Oct 29. doi: 10.1037/bne0000391. Epub ahead of print. PMID: 33119328.


5: Rawji V, Rocchi L, Foltynie T, Rothwell JC, Jahanshahi M. Ropinirole, a dopamine agonist with high D3 affinity, reduces proactive inhibition: A double-blind, placebo-controlled study in healthy adults. Neuropharmacology. 2020 Nov 15;179:108278. doi: 10.1016/j.neuropharm.2020.108278. Epub 2020 Aug 19. PMID: 32827517; PMCID: PMC7575901.


6: Chatzitaki AT, Jesus S, Karavasili C, Andreadis D, Fatouros DG, Borges O. Chitosan-coated PLGA nanoparticles for the nasal delivery of ropinirole hydrochloride: In vitro and ex vivo evaluation of efficacy and safety. Int J Pharm. 2020 Nov 15;589:119776. doi: 10.1016/j.ijpharm.2020.119776. Epub 2020 Aug 17. PMID: 32818538.


7: Rymbai E, Sugumar D, Saravanan J, Divakar S. Ropinirole, a potential drug for systematic repositioning based on side effect profile for management and treatment of breast cancer. Med Hypotheses. 2020 Nov;144:110156. doi: 10.1016/j.mehy.2020.110156. Epub 2020 Aug 2. PMID: 32763725.


8: Wang Y, Bouabid S, Darvas M, Zhou FM. The antiparkinson drug ropinirole inhibits movement in a Parkinson's disease mouse model with residual dopamine neurons. Exp Neurol. 2020 Nov;333:113427. doi: 10.1016/j.expneurol.2020.113427. Epub 2020 Jul 29. PMID: 32735872.


9: Naz F, Rahul, Fatima M, Naseem S, Khan W, Mondal AC, Siddique YH. Ropinirole silver nanocomposite attenuates neurodegeneration in the transgenic Drosophila melanogaster model of Parkinson's disease. Neuropharmacology. 2020 Oct 15;177:108216. doi: 10.1016/j.neuropharm.2020.108216. Epub 2020 Jul 21. PMID: 32707222.


10: Kuang Z, Huang T, Li D, Zhao D, Jin J, Lin J, Zhu W, Chen W, Li M, Shen W. Structure Elucidation and Mechanistic Study of a New Dimeric Degradant in Ropinirole Hydrochloride Extended-Release Tablets. Pharm Res. 2020 Jul 8;37(7):136. doi: 10.1007/s11095-020-02863-3. PMID: 32642838.


11: Rewane A, Nagalli S. Ropinirole. 2020 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 32119419.


12: Tome T, Obreza A, Časar Z. Developing an Improved UHPLC Method for Efficient Determination of European Pharmacopeia Process-Related Impurities in Ropinirole Hydrochloride Using Analytical Quality by Design Principles. Molecules. 2020 Jun 10;25(11):2691. doi: 10.3390/molecules25112691. PMID: 32531959; PMCID: PMC7321168.


13: Dudhipala N, Gorre T. Neuroprotective Effect of Ropinirole Lipid Nanoparticles Enriched Hydrogel for Parkinson's Disease: In Vitro, Ex Vivo, Pharmacokinetic and Pharmacodynamic Evaluation. Pharmaceutics. 2020 May 13;12(5):448. doi: 10.3390/pharmaceutics12050448. PMID: 32414195; PMCID: PMC7284436.


14: Hattori N, Mochizuki H, Hasegawa K, Nomoto M, Uchida E, Terahara T, Okawa K, Fukuta H. Ropinirole Patch Versus Placebo, Ropinirole Extended-Release Tablet in Advanced Parkinson's Disease. Mov Disord. 2020 Sep;35(9):1565-1573. doi: 10.1002/mds.28071. Epub 2020 May 12. PMID: 32396257.


15: Gungabissoon U, Kirichek O, El Baou C, Galwey N. Comparison of long-term use of prolonged-release ropinirole and immediate-release dopamine agonists in an observational study in patients with Parkinson's disease. Pharmacoepidemiol Drug Saf. 2020 May;29(5):591-598. doi: 10.1002/pds.4986. Epub 2020 Mar 9. PMID: 32153056; PMCID: PMC7317950.


16: Neo S, Xu Z. Prolonged penile erection in the absence of sexual stimulation following ropinirole use for restless legs syndrome. Sleep Med. 2020 Apr;68:20. doi: 10.1016/j.sleep.2019.07.029. Epub 2019 Sep 14. PMID: 32018186.


17: Okano H, Yasuda D, Fujimori K, Morimoto S, Takahashi S. Ropinirole, a New ALS Drug Candidate Developed Using iPSCs. Trends Pharmacol Sci. 2020 Feb;41(2):99-109. doi: 10.1016/j.tips.2019.12.002. Epub 2020 Jan 8. PMID: 31926602.


18: Andrabi SS, Tabassum H, Parveen S, Parvez S. Ropinirole induces neuroprotection following reperfusion-promoted mitochondrial dysfunction after focal cerebral ischemia in Wistar rats. Neurotoxicology. 2020 Mar;77:94-104. doi: 10.1016/j.neuro.2019.12.004. Epub 2019 Dec 6. PMID: 31816341.


19: Takahashi S, Morimoto S, Fukushima K, Nakahara J, Okano H. [Ropinirole Hydrochloride for ALS]. Brain Nerve. 2019 Nov;71(11):1279-1288. Japanese. doi: 10.11477/mf.1416201438. PMID: 31722314.


20: Takahashi S, Morimoto S, Okano H. [Ropinirole Hydrochloride, a Candidate Drug for ALS Treatment]. Brain Nerve. 2019 Sep;71(9):943-952. Japanese. doi: 10.11477/mf.1416201386. PMID: 31506396.